RxDoctor Payments Data

Jeffrey Peller, MD

Rheumatology · Rome, GANPI 1497810808

Payments from drug & device makers

$3,047in general payments, 2019–2025

Across 163 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$822
  • AbbVie$748
  • Pfizer$326
  • Johnson & Johnson$265
  • Novartis$206
  • Aurinia Pharma U.S., Inc.$139
  • plus $540 from 11 others

What the payments were for

  • Food & beverage$2,77791%
  • Education$2709%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,047 in reported general payments places this provider in the 40th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$5,423,358
Medicare patients
902
Services billed
272,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab169$1,345,958
Enbrel SureclickEtanercept131$1,008,687
Xeljanz XrTofacitinib Citrate83$556,787
EnbrelEtanercept51$410,192
Humira(Cf)Adalimumab20$242,732
Cosentyx Sensoready PenSecukinumab18$136,123
Humira PenAdalimumab18$117,502
RinvoqUpadacitinib16$109,490
XeljanzTofacitinib Citrate17$96,911
ProliaDenosumab56$95,783
HumiraAdalimumab11$88,408
OtezlaApremilast13$63,830
BenlystaBelimumab11$52,278
Hydroxychloroquine Sulfate577$22,355
MethotrexateMethotrexate Sodium695$12,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Prolia, Otezla$822$569,805120 claims
AbbVieHumira(Cf), Rinvoq, Humira$748$440,63047 claims
PfizerXeljanz$326$96,91117 claims
GSKBenlysta$107$52,27811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →